CoChat

Cabergoline for Cushing’s disease: a large retrospective multicenter study

Ferriere, A, Cortet, C, Chanson, P, Delemer, B, Caron, P, Chabre, O, Reznik, Y, Bertherat, J, Rohmer, V, Briet, C, Raingeard, I, Castinetti, F, Beckers, A, Vroonen, L, Maiter, D, Cephise-Velayoudom, F L, Nunes, M L, Haissaguerre, M, Tabarin, A · 2017 · European Journal of Endocrinology
Cited by 115

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Objective: The efficacy of cabergoline in Cushing’s disease (CD) is controversial. The aim of this study was to assess the efficacy and tolerability of cabergoline in a large contemporary cohort of patients with CD. Design: We conducted a retrospective multicenter study from thirteen French and Belgian university hospitals. Methods: Sixty-two patients with CD received cabergoline monotherapy or add-on therapy. Symptom score, biological markers of hypercortisolism and adverse effects were recorded. Results: Twenty-one (40%) of 53 patients who received cabergoline monotherapy had normal urinary free cortisol (UFC) values within 12 months (complete responders), and five of these patients developed corticotropic insufficiency. The fall in UFC was associated with significant reductions in midnight cortisol and plasma ACTH, and with clinical improvement. Compared to other patients, complete responders had similar median baseline UFC (2.0 vs 2.5xULN) and plasma prolactin concentrations but received lower doses of cabergoline (1.5 vs 3.5 mg/week,P < 0.05). During long-term treatment (>12 months), cabergoline was withdrawn in 28% of complete responders because of treatment escape or intolerance. Overall, sustained control of hypercortisolism was obtained in 23% of patients for 32.5 months (19–105). Nine patients on steroidogenesis inhibitors received cabergoline add-on therapy for 19 months (1–240). Hypercortisolism was controlled in 56% of these patients during the first year of treatment with cabergoline at 1.0 mg/week (0.5–3.5). Conclusions: About 20–25% of CD patients are good responders to cabergoline therapy allowing long-term control of hypercortisolism at relatively low dosages and with acceptable tolerability. No single parameter, including the baseline UFC and prolactin levels, predicted the response to cabergoline.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/eje-16-0662

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 115

Metadata

Authors
Ferriere, A., Cortet, C., Chanson, P., Delemer, B., Caron, P., Chabre, O., Reznik, Y., Bertherat, J., Rohmer, V, Briet, C., Raingeard, I., Castinetti, F., Beckers, A., Vroonen, L., Maiter, D., Cephise-Velayoudom, F. L., Nunes, M. L., Haissaguerre, M., & Tabarin, A.
Venue
European Journal of Endocrinology
Published
2017-03
Volume
176
Issue
3
Pages
305-314
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2561160044
Cited by
115
References
13
FWCI
9.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cabergoline for Cushing’s disease: a large retrospective multicenter study. https://app.cochat.ai/papers/10.1530/eje-16-0662
The paper
Ferriere, A., Cortet, C., Chanson, P., Delemer, B., Caron, P., Chabre, O., Reznik, Y., Bertherat, J., Rohmer, V, Briet, C., Raingeard, I., Castinetti, F., Beckers, A., Vroonen, L., Maiter, D., Cephise-Velayoudom, F. L., Nunes, M. L., Haissaguerre, M., & Tabarin, A. (2017). Cabergoline for Cushing’s disease: a large retrospective multicenter study. European Journal of Endocrinology. https://doi.org/10.1530/eje-16-0662

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.